Literature DB >> 22872053

Percutaneous coronary intervention versus optimal medical therapy in stable coronary artery disease: a systematic review and meta-analysis of randomized clinical trials.

Seema Pursnani1, Frederick Korley, Ravindra Gopaul, Pushkar Kanade, Newry Chandra, Richard E Shaw, Sripal Bangalore.   

Abstract

BACKGROUND: The role of percutaneous coronary intervention (PCI) in the management of stable coronary artery disease remains controversial. Given advancements in medical therapies and stent technology over the last decade, we sought to evaluate whether PCI, when added to medical therapy, improves outcomes when compared with medical therapy alone. METHODS AND
RESULTS: We performed a systematic review and meta-analysis, searching PubMed, EMBASE, and CENTRAL databases, until January 2012, for randomized clinical trials comparing revascularization with PCI to optimal medical therapy (OMT) in patients with stable coronary artery disease. The primary outcome was all-cause mortality, and secondary outcomes included cardiovascular death, nonfatal myocardial infarction, subsequent revascularization, and freedom from angina. Primary analyses were based on longest available follow-up with secondary analyses stratified by trial duration, with short-term (≤1 year), intermediate (1-5 years), and long-term (≥5 years) time points. We identified 12 randomized clinical trials enrolling 7182 participants who fulfilled our inclusion criteria. For the primary analyses, when compared with OMT, PCI was associated with no significant improvement in mortality (risk ratio [RR], 0.85; 95% CI, 0.71-1.01), cardiac death (RR, 0.71; 95% CI, 0.47-1.06), nonfatal myocardial infarction (RR, 0.93; 95% CI, 0.70-1.24), or repeat revascularization (RR, 0.93; 95% CI, 0.76-1.14), with consistent results over all follow-up time points. Sensitivity analysis restricted to studies in which there was >50% stent use showed attenuation in the effect size for all-cause mortality (RR, 0.93; 95% CI, 0.78-1.11) with PCI. However, for freedom from angina, there was a significant improved outcome with PCI, as compared with the OMT group (RR, 1.20; 95% CI, 1.06-1.37), evident at all of the follow-up time points.
CONCLUSIONS: In this most rigorous and comprehensive analysis in patients with stable coronary artery disease, PCI, as compared with OMT, did not reduce the risk of mortality, cardiovascular death, nonfatal myocardial infarction, or revascularization. PCI, however, provided a greater angina relief compared with OMT alone, larger studies with sufficient power are required to prove this conclusively.

Entities:  

Mesh:

Year:  2012        PMID: 22872053     DOI: 10.1161/CIRCINTERVENTIONS.112.970954

Source DB:  PubMed          Journal:  Circ Cardiovasc Interv        ISSN: 1941-7640            Impact factor:   6.546


  52 in total

1.  Choosing between percutaneous coronary intervention and coronary artery bypass graft surgery for nondiabetic patients with multivessel disease.

Authors:  Aeshita Dwivedi; Sripal Bangalore
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

2.  [Percutaneous coronary intervention in stable angina pectoris : Objective randomised blinded investigation with optimal medical therapy of angioplasty in stable angina (ORBITA) trial].

Authors:  C Kugler; J Wöhrle; S Nitschmann
Journal:  Internist (Berl)       Date:  2018-09       Impact factor: 0.743

Review 3.  [National disease management guidelines (NVL) for chronic CAD : What is new, what is particularly important?].

Authors:  K Werdan
Journal:  Herz       Date:  2016-09       Impact factor: 1.443

Review 4.  Comparison of mid- to long-term clinical outcomes between anatomical testing and usual care in patients with suspected coronary artery disease: A meta-analysis of randomized trials.

Authors:  In-Chang Hwang; Sol Ji Choi; Ji Eun Choi; Eun-Bi Ko; Jae Kyung Suh; Insun Choi; Hyun-Jae Kang; Yong-Jin Kim; Joo Youn Kim
Journal:  Clin Cardiol       Date:  2017-09-15       Impact factor: 2.882

5.  Percutaneous Coronary Intervention Versus Optimal Medical Therapy for Stable Angina in Advanced CKD: A Decision Analysis.

Authors:  Aisha Khattak; Ernest I Mandel; Matthew R Reynolds; David M Charytan
Journal:  Am J Kidney Dis       Date:  2016-09-16       Impact factor: 8.860

6.  Alpha-crystallin: an ATP-independent complete molecular chaperone toward sorbitol dehydrogenase.

Authors:  I Marini; R Moschini; A Del Corso; U Mura
Journal:  Cell Mol Life Sci       Date:  2005-03       Impact factor: 9.261

7.  Implementation of a cardiac PET stress program: comparison of outcomes to the preceding SPECT era.

Authors:  Stacey Knight; David B Min; Viet T Le; Kent G Meredith; Ritesh Dhar; Santanu Biswas; Kurt R Jensen; Steven M Mason; Jon-David Ethington; Donald L Lappe; Joseph B Muhlestein; Jeffrey L Anderson; Kirk U Knowlton
Journal:  JCI Insight       Date:  2018-05-03

8.  Coronary artery disease: to cath or not to cath? When and how best to cath: those are the remaining questions.

Authors:  Roberta Rossini; Giuseppe Musumeci; Eliano Pio Navarese; Giuseppe Tarantini
Journal:  Am J Cardiovasc Dis       Date:  2013-02-17

Review 9.  Medical Therapy With Versus Without Revascularization in Stable Patients With Moderate and Severe Ischemia: The Case for Community Equipoise.

Authors:  Gregg W Stone; Judith S Hochman; David O Williams; William E Boden; T Bruce Ferguson; Robert A Harrington; David J Maron
Journal:  J Am Coll Cardiol       Date:  2015-11-23       Impact factor: 24.094

Review 10.  Challenges with Evidence-Based Management of Stable Ischemic Heart Disease.

Authors:  Amit V Patel; Sripal Bangalore
Journal:  Curr Cardiol Rep       Date:  2017-02       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.